Chapter 6 Clinical and Experimental Electroencephalography

Borenstein, P; Dongier, M; Fink, Max; Florio, Vincenzo De; M., T.; Longo, Vincenzo; Mellerio, F; Naquet, R; Pampiglione, G.; Titeca, J; Verdeaux, G

doi:10.1159/000387378

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Psychostimulants and hallucinogens alter brain wave activities 43,44 . Consistent with other hallucinogens, 45,46 25B‐NBOMe and DOI increased delta wave and reduced gamma wave activity.…”

Section: Discussionmentioning

confidence: 59%

See 1 more Smart Citation

25B‐NBOMe, a novel N‐2‐methoxybenzyl‐phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential

et al. 2019

View full text Add to dashboard Cite

An increasing number of N-2-methoxybenzyl-phenethylamine (NBOMe) derivatives are being misused worldwide, including the potent hallucinogen 2-(4-bromo-2,5dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe). However, the number of studies characterizing the abuse potential and psychopharmacological properties of 25B-NBOMe is limited; thus, we examined its rewarding and reinforcing effects using conditioned place preference (CPP) and self-administration (SA) tests. Pretreatment with SCH23390 (SCH), Haloperidol (HAL), and ketanserin (KS), antagonists of dopamine D1 (DRD 1), dopamine D2 (DRD 2), and serotonin 2A (5-HT 2A receptor) receptors, respectively, was utilized during a CPP test to investigate the involvement of the dopaminergic and serotonergic systems in 25B-NBOMemediated effects. We also examined the effects of 25B-NBOMe on the expression of dopamine-related proteins in the nucleus accumbens (NAcc) and ventral tegmental area (VTA). Then, we measured the dopamine level, phosphorylated CREB (p-CREB), deltaFosB (ΔFosB), and brain-derived neurotrophic factor (BDNF) in the NAcc. In addition, we explored the involvement of 5-HT 2A receptors in the 25B-NBOMeinduced head twitch response (HTR). We also examined the effects of 25B-NBOMe on brain wave activity using electroencephalography. 25B-NBOMe elicited CPP and SA. SCH and HAL blocked 25B-NBOMe-induced CPP, whereas KS did not. Moreover, 25B-NBOMe altered the DRD 1 , DRD 2 , and dopamine transporter expression and increased dopamine levels. It also induced changes in p-CREB, ΔFosB, and BDNF expression. 25B-NBOMe induced HTR and increased 5-HT 2A receptor mRNA levels, effects inhibited by KS. Furthermore, 25B-NBOMe altered delta and gamma wave activity, which was normalized by SCH and HAL. These findings show Raly James Perez Custodio and Leandro Val Sayson have contributed equally to this manuscript.

show abstract

“…Psychostimulants and hallucinogens alter brain wave activities 43,44 . Consistent with other hallucinogens, 45,46 25B‐NBOMe and DOI increased delta wave and reduced gamma wave activity.…”

Section: Discussionmentioning

confidence: 59%

“…NBOMe, METH, and DOI increased the delta waves in mice. G-I, The EEG absolute power within the gamma(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45) frequencies (μV 2 ) in mice. Both 25B-NBOMe and DOI decreased the delta waves in mice, whereas METH increased them.…”

mentioning

confidence: 99%

25B‐NBOMe, a novel N‐2‐methoxybenzyl‐phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential

et al. 2019

View full text Add to dashboard Cite

show abstract

Neuroleptic neurotoxicity; electro-clinical aspects

Sweden

1984

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

The clinical signs of psychotropic drug-induced neurotoxicity can be based on different neurochemical actions. Patients presenting with neurotoxic signs such as epileptic phenomena and altered states of consciousness are represented. Predisposing factors, EEG and clinical data and electro-clinical correlations are discussed and related to age and the drugs involved. It appears that in young patients, electro-clinical syndromes exist differentiating early from late-onset cerebral reactions. In the elderly, signs of neurotoxicity usually show an early onset and particular electro-clinical features. Finally pathogenetic considerations are reviewed.

show abstract

Chapter 6 Clinical and Experimental Electroencephalography

Cited by 2 publications

References 0 publications

25B‐NBOMe, a novel N‐2‐methoxybenzyl‐phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential

25B‐NBOMe, a novel N‐2‐methoxybenzyl‐phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential

Neuroleptic neurotoxicity; electro-clinical aspects

Contact Info

Product

Resources

About